Global Cancer Tumor Profiling Market Size, Status and Forecast 2019-2025

Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.
The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.
In 2018, the global Cancer Tumor Profiling market size was 30200 million US$ and it is expected to reach 115600 million US$ by the end of 2025, with a CAGR of 18.2% during 2019-2025.

This report focuses on the global Cancer Tumor Profiling status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Tumor Profiling development in United States, Europe and China.

The key players covered in this study
Qiagen N.V.
Roche Molecular Systems Inc.
Abott Molecular
Illumina Inc.
NeoGenomics Laboratories
HTG Molecular Diagnostic
Genomic Health Inc.
Hologic Gen-Probe
BD Biosciences
Siemens Healthineers
Claris Life Sciences
Personal Genome Diagnostics, Inc.
Perthera, Inc.
Foundation Medicine, Inc
V., Strand
ApoCell
Contextual Genomics
Agendia
GenScript

Market segment by Type, the product can be split into
Next-generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Microarray
Others

Market segment by Application, split into
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Research Applications

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Cancer Tumor Profiling status, future forecast, growth opportunity, key market and key players.
To present the Cancer Tumor Profiling development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Cancer Tumor Profiling are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.